Brad Robling
Direktor/Vorstandsmitglied bei Auron Therapeutics, Inc.
Profil
Brad Robling is currently a Director at Auron Therapeutics, Inc. He previously worked as a Director-Investor Relations at Eli Lilly & Co.
Aktive Positionen von Brad Robling
| Unternehmen | Position | Beginn |
|---|---|---|
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Brad Robling
| Unternehmen | Position | Ende |
|---|---|---|
| ELI LILLY AND COMPANY | Public Communications Contact | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |